- FY Adjusted EPS Forecast Narrowed: Now expected to be between $13.05 and $13.15, previously expected to be between $12.95 and $13.15. Analyst estimate was $13.04.
- Revenue Forecast: Expected to be about $20.1 billion, previously expected to be between $20.1 billion and $20.3 billion.
- Third Quarter Results:
- Adjusted EPS: $3.50, beating the estimate of $3.31.
- Revenue: $4.99 billion, exceeding the estimate of $4.99 billion.
- Medical Revenue: $2.56 billion, estimate was $2.53 billion.
- Medication Delivery Solutions Revenue: $1.12 billion, estimate was $1.1 billion.
- Medication Management Solutions Revenue: $840 million, estimate was $832.1 million.
- Pharmaceutical Systems Revenue: $594 million, estimate was $597.5 million.
- Life Sciences Revenue: $1.26 billion, estimate was $1.27 billion.
- Integrated Diagnostic Solutions Revenue: $896 million, estimate was $888.9 million.
- Biosciences Revenue: $363 million, estimate was $384.2 million.
- Interventional Revenue: $1.24 billion, estimate was $1.26 billion.
- Surgery Revenue: $376 million, estimate was $380.7 million.
- Peripheral Intervention Revenue: $488 million, estimate was $503.4 million.
- Urology and Critical Care Revenue: $375 million, estimate was $376 million.
- Revenue Growth Guidance: Updated fiscal 2024 GAAP revenue growth guidance to approximately 3.7% and organic revenue growth guidance to 5.0% to 5.25%.
- Adjusted Diluted EPS Guidance Increase: Adjusted diluted EPS guidance increased by 5 cents at the midpoint to a range of $13.05 to $13.15, driven by strong margin performance and updated margin outlook for the full fiscal year.
- Investment Analyst Ratings: 15 buys, 3 holds, 0 sells.
A look at Becton Dickinson and Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Becton Dickinson and Co has received consistent scores across various factors including Value, Dividend, Growth, Resilience, and Momentum, all rated at 3. This indicates a balanced outlook for the company in the long term. Becton Dickinson and Co, a global medical technology company, focuses on the development and sale of medical devices, instrument systems, and reagents. With steady scores across key aspects, the company seems to have a stable foundation and potential for growth in the healthcare industry.
Becton Dickinson and Co‘s Smartkarma Smart Scores suggest a moderate and well-rounded performance in terms of its future prospects. The company’s activities in providing medical solutions to healthcare institutions, researchers, laboratories, and the pharmaceutical sector position it well for continued success. With consistent ratings in Value, Dividend, Growth, Resilience, and Momentum, Becton Dickinson and Co appears to be on a steady path for long-term sustainability and potential growth in the evolving medical technology landscape.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
